Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Analysis of the IFNgamma induced pathways in murine macrophages

ABSTRACT: Analysis of the IFNgamma induced pathways in murine macrophages

PROVIDER: PRJNA478256 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7444560.fastq.gz	Fastqsanger.gz
	SRR7444570.fastq.gz	Fastqsanger.gz
	SRR7444561.fastq.gz	Fastqsanger.gz
	SRR7444571.fastq.gz	Fastqsanger.gz
	SRR7444562.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Analysis of the IFNgamma induced pathways in murine macrophages

Project description:Macrophages derived from the CH3 mice were treated with the increasing concentrations of the IFNgamma followed by the RNA-Seq analysis.

2019-01-01 | GSE116364 | GEO

IFNgamma and 1a,25(OH)2D3 dependent gene expression in bone marrow derived macrophages

Project description:Gene expression profiling of macrophages derived from WT and Vdr deficient mice after stimulation with IFNgamma and/or 1alpha,25(OH)2D3 Keywords = macrophages Keywords = VDR Keywords = activated vitamin D3 Keywords = IFNgamma Keywords = KO mice Keywords: dose response

2005-04-21 | GSE2421 | GEO

RNAseq of oncogene-induced senescent murine macrophages

Project description:RNAseq of oncogene-induced senescent murine macrophages

| PRJNA642870 | ENA

Whole-genome expression analysis in IFNgamma stimulated bone marrow-derived macrophages from transgenic mice expressing only non-nuclear mutant Socs1

Project description:To study the role of SOCS1 in the cell nucleus in vivo, we generated a transgenic mouse model using a bacterial artificial chromosome (BAC) containing a mutated Socs1 locus (non-nuclear Socs1ÎNLS), GFP and firefly Luciferase, termed MGL. MGL transgenic mice expressing only non-nuclear mutant Socs1 (Socs1-/- MGLtg mice) survive the early lethal phenotype of Socs1-/- mice that die within 3 weeks due to excessive immune signaling, mainly depending on hyperresponsiveness to IFNgamma. Therefore, we suggested that classical IFNgamma signaling might still be efficiently regulated by SOCS1ÎNLS. To prove this hypothesis, bone marrow-derived macrophages (BMMs) from Socs1-/- MGLtg mice and the control group (Socs1+/- MGLtg mice) were stimulated with IFNgamma for 24 h and subjected to whole-genome expression analysis.

2016-11-10 | E-MTAB-4938 | biostudies-arrayexpress

Transcription profiling of macrophages derived from WT and Vdr dificient mice after stimulation with IFNgamma and/or 1alpha,25(OH)2D3 to study molecular mechanisms of macrophage activation

Project description:Gene expression profiling of macrophages derived from WT and Vdr deficient mice after stimulation with IFNgamma and/or 1alpha,25(OH)2D3

2007-08-31 | E-GEOD-2421 | biostudies-arrayexpress

TLR2/6 agonists and IFNgamma induce CXCL10 from melanoma

Project description:Clinical approaches to treat advanced melanoma include immune therapies, whose benefits depend on tumor-reactive T-cells to infiltrate metastases. However, most tumors lack significant immune infiltration prior to therapy, and some immune therapies are hindered by a persistent lack of immune cell infiltration. CXCL10 has been implicated as a critical chemokine supporting T-cell migration into tumors; thus agents that induce CXCL10 in tumors may improve patient responses to systemic immune therapy. We find that melanoma cells treated with TLR2/6 agonists (MALP-2 or FSL-1) and interferon-gamma (IFNgamma) upregulate CXCL10 production, when compared to IFNgamma treatment alone or no treatment. Gene profiling of melanoma cells lines treated with TLR2/6 agonists and IFNgamma demonstrate that a selective profile of genes are induced which may be favorable for promoting immune cell infiltration of tumors. TLR2 and TLR6 are widely expressed on human melanoma cells, and treatment of melanoma cells with TLR2/6 agonists and IFNgamma does not hinder melanoma cell apoptosis or promote proliferation. Furthermore, melanoma cells from surgically resected patient tumors upregulate CXCL10 production after treatment with TLR2/6 agonists and IFNgamma when compared to treatment with either agent alone. Collectively, these data identify TLR2/6 agonists and IFNgamma as a novel target for promoting CXCL10 production directly from melanoma cells.

2015-11-22 | GSE64506 | GEO

Immunologic Effects of a Peptide Vaccine with Intralesional IFNgamma For Treatment of Melanoma

Project description:Introduction: Optimal approaches to induce T-cell infiltration of tumors are not known. Chemokines CXCL9, CXCL10, and CXCL11 support effector T-cell recruitment, and may be induced by IFNgamma. This study tests the hypothesis that intratumoral administration of IFNgamma will induce CXCL9-11, and will induce T-cell recruitment and anti-tumor immune signatures in melanoma metastases. Patients and Methods: Nine eligible patients were immunized with a vaccine comprised of 12 class I MHC-restricted melanoma peptides (12MP) and received IFNgamma intratumorally. Effects on the tumor microenvironment (TME) were evaluated in sequential tumor biopsies. Adverse events (AE; CTCAE v4) were recorded. T-cell responses to vaccination were assessed in peripheral blood (PBMC) by IFNgamma ELIspot assay. Tumor biopsies were evaluated for immune cell infiltration, chemokine protein expression and gene expression. Results: Vaccination and intratumoral administration of IFNgamma were well tolerated. Circulating T-cell responses to vaccine were detected in 6 of 9 patients. IFNgamma increased production of chemokines CXCL10, CXCL11, and CCL5 in patient tumors. Neither vaccination alone nor the addition of IFNgamma promoted immune cell infiltration or induced anti-tumor immune gene signatures. Conclusion: The cancer vaccine did not significantly increase T-cell infiltration of tumors. This study provides intriguing findings highlighting some of the limitations of intratumoral IFNgamma treatment. Although IFNgamma is pivotal in anti-tumor immunity, single intratumoral injection may induce secondary immune regulation that paradoxically limits immune infiltration and effector functions. Therefore, alternate dosing strategies or additional combinatorial treatments may be needed to optimally promote trafficking and retention of T-cells in tumor, which merit further study.

2017-03-01 | GSE79741 | GEO

Mycobacterium tuberculosis induced interferon pathways distinguish responses of Human Alveolar Macrophages from Monocyte-Derived Macrophages

Project description:Mycobacterium tuberculosis induced interferon pathways distinguish responses of Human Alveolar Macrophages from Monocyte-Derived Macrophages

| PRJNA989153 | ENA

Hypoxia-induced translational profiles of murine bone marrow derived macrophages (BMDM)

Project description:Hypoxia-induced translational profiles of murine bone marrow derived macrophages (BMDM)

| PRJNA805237 | ENA

Hypoxia-induced translational profiles of murine fetal liver derived macrophages (FLDM)

Project description:Hypoxia-induced translational profiles of murine fetal liver derived macrophages (FLDM)

| PRJNA808083 | ENA